BeyondSpring Inc. (BYSI)

Market Cap	33.96M
Revenue (ttm)	1.35M
Net Income (ttm)	-33.28M
Shares Out	38.92M
EPS (ttm)	-0.85
PE Ratio	n/a
Forward PE	10.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,446
Open	0.890
Previous Close	0.873
Day's Range	0.850 - 0.910
52-Week Range	0.550 - 3.450
Beta	-0.02
Analysts	Buy
Price Target	1.25 (+42.05%)
Earnings Date	Dec 19, 2023

About BYSI

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of no...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 9, 2017
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: BYSI

Financial Performance

In 2022, BeyondSpring's revenue was $1.35 million, a change of 0.00% compared to the previous year's $1.35 million. Losses were -$33.28 million, -48.15% less than in 2021.

Analyst Forecast

According to one analyst, the rating for BYSI stock is "Buy" and the 12-month stock price forecast is $1.25.

Price Target

$1.25

(42.05% upside)

Analyst Consensus: Buy